Tumor Necrosis Factor Alpha Inhibition for Inflammatory Bowel Disease after Liver Transplant for Primary Sclerosing Cholangitis

BACKGROUND: Outcome data regarding the use of tumor necrosis factor alpha inhibitors (anti-TNFα) in patients with inflammatory bowel disease (IBD) after liver transplant (LT) for primary sclerosing cholangitis (PSC) are scant. METHODS: We performed a retrospective chart review to investigate outcome...

Descripción completa

Detalles Bibliográficos
Autores principales: Parekh, Ravish, Abdulhamid, Ahmed, Trudeau, Sheri, Kaur, Nirmal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5976998/
https://www.ncbi.nlm.nih.gov/pubmed/29862092
http://dx.doi.org/10.1155/2018/1015408

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5976998/
https://www.ncbi.nlm.nih.gov/pubmed/29862092
http://dx.doi.org/10.1155/2018/1015408

Ejemplares similares